Notwithstanding positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. These organizations are https://brianrtbi605087.blogdemls.com/41768456/the-medication-faces-is-dealing-with-pharmacy-benefit-manager-hurdles-a-review-of-access-battles